Genentech pulls Raptiva over PML risk

Share this article:
Genentech and FDA announced the withdrawal of psoriasis treatment Raptiva due to a risk of progressive multifocal leukoencephalopathy (PML), a rare and deadly viral brain infection.

The agency added a black-box warning to the biologic's labeling in October, cautioning of the risk of PML as well as bacterial sepsis, viral meningitis and invasive fungal disease for patients on the drug. The Roche-owned company issued a “Dear Patient” letter in March announcing a new Raptiva medication guide and warning of the PML risk. The drug will no longer be available after June 8.

Indicated for chronic moderate to severe plaque psoriasis in those 18 and over, Raptiva helps tamp down flare-ups by suppressing the immune system. That, however, can open the door to the JC virus thought to be behind PML, which destroys the white matter in the brain. PML was often seen in AIDS patients before the advent of antiretroviral drugs.

The treatment won FDA approval in late 2003. Since then, it has been used to treat around 46,000 patients worldwide. There have been three diagnosed cases of PML in Raptiva patients and one case of a patient treated with Raptiva who developed progressive neurologic symptoms and died of unknown causes. The company estimates that around 2,000 in the US are currently using the treatment.   

US sales of Raptiva in 2008 brought in $108 million.

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...